Trial Profile
A Two-Part Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Repeat IV Doses of GSK2140944 in Healthy Adult Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Gepotidacin (Primary) ; Gepotidacin (Primary)
- Indications Bacterial infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 30 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 13 Feb 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Sep 2013 to 1 Feb 2014.
- 13 Feb 2014 According to the ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.